Crestor vs Repatha: Switching Between Rosuvastatin and Evolocumab

How These Two Drugs Lower LDL Through Different Pathways

Rosuvastatin blocks HMG-CoA reductase in the liver, reducing cholesterol synthesis and upregulating LDL receptors on hepatocyte surfaces. This pulls circulating LDL particles out of the bloodstream. At the maximum 40 mg dose, rosuvastatin achieves roughly 55% LDL reduction from baseline, making it one of the most potent statins available 1.

Evolocumab works downstream. It binds and neutralizes PCSK9, a protein that normally degrades those same LDL receptors after they deliver their cargo. With PCSK9 blocked, more LDL receptors recycle back to the cell surface, clearing additional LDL from circulation. In the FOURIER trial (N=27,564), evolocumab reduced LDL by a median of 59% when added to background statin therapy, bringing the median LDL to 30 mg/dL 2. The two mechanisms are complementary. A statin increases LDL receptor production; a PCSK9 inhibitor keeps those receptors active longer. That is why guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) position PCSK9 inhibitors as add-on therapy for patients already on maximally tolerated statins who still exceed their LDL threshold 3.

The distinction matters for switching decisions. Replacing a statin with Repatha (rather than adding it) removes one mechanism entirely. Some patients require that trade-off. Most benefit from combination.

Cardiovascular Outcomes: What JUPITER and FOURIER Actually Showed

The JUPITER trial (N=17,802) randomized apparently healthy adults with LDL <130 mg/dL but high-sensitivity C-reactive protein (hsCRP) of 2 mg/L or higher to rosuvastatin 20 mg or placebo. The trial was stopped early at a median 1.9 years of follow-up after rosuvastatin demonstrated a 44% relative reduction in the composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death (HR 0.56; 95% CI 0.46-0.69; P<0.00001) 4.

FOURIER enrolled a different population: patients with established atherosclerotic cardiovascular disease (ASCVD) already receiving statin therapy. Evolocumab produced a 15% relative reduction in the primary composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization (HR 0.85; 95% CI 0.79-0.92; P<0.001) over a median 2.2 years 2.

No head-to-head cardiovascular outcomes trial has compared rosuvastatin directly against evolocumab as monotherapies. The populations, baselines, and background therapies differ too much for a clean cross-trial comparison. What the data do confirm: statins provide the foundational CV risk reduction, and PCSK9 inhibitors deliver incremental benefit on top of that foundation.

A longer-term analysis, the FOURIER-OLE open-label extension, followed patients for a median of 5 years on evolocumab and found a 15% reduction in cardiovascular death (nominal P=0.01), suggesting durable benefit from sustained very-low LDL levels 5.

When Switching From Crestor to Repatha Makes Clinical Sense

Three scenarios drive the transition from rosuvastatin to evolocumab in clinical practice.

Statin intolerance. Roughly 5-10% of statin users report myalgia severe enough to limit adherence. The 2018 AHA/ACC cholesterol guideline recommends trying at least two different statins (including dose reduction or alternate-day dosing) before concluding true intolerance 3. For patients who genuinely cannot tolerate any statin regimen, evolocumab monotherapy becomes an option. The GAUSS-3 trial demonstrated that among statin-intolerant patients, evolocumab lowered LDL by 52.8% compared to 16.7% with ezetimibe, with muscle symptoms occurring in only 0.7% of evolocumab-treated patients versus 28.8% of those re-challenged with atorvastatin 6.

Failure to reach LDL targets. Patients with ASCVD and very high-risk features should target LDL <70 mg/dL per AHA/ACC guidelines, with a <55 mg/dL threshold in the European Society of Cardiology (ESC) 2019 guidelines 7. A patient on rosuvastatin 40 mg with a baseline LDL of 190 mg/dL may only reach approximately 85 mg/dL. Adding evolocumab to that regimen can push the LDL below 30 mg/dL. This is an add-on, not a full switch.

Familial hypercholesterolemia (FH). Patients with heterozygous FH often start with baseline LDL above 190 mg/dL. Even maximum-dose rosuvastatin plus ezetimibe may leave these patients well above goal. The RUTHERFORD-2 trial showed evolocumab reduced LDL by 59.2% in heterozygous FH patients already on lipid-lowering therapy 8.

How to Execute the Switch: Practical Prescribing Steps

The logistics differ based on whether the patient is adding Repatha to existing statin therapy or replacing the statin entirely.

Adding Repatha to Crestor (most common approach). The patient continues rosuvastatin at their current dose. Evolocumab is initiated at 140 mg subcutaneously every 2 weeks, or 420 mg once monthly. No washout period is required. LDL should be rechecked 4-8 weeks after starting to confirm response 9.

Replacing Crestor with Repatha (statin-intolerant patients). The statin is discontinued. Many clinicians allow a 2-4 week washout to let statin-related myalgia resolve before attributing any new symptoms to evolocumab. Evolocumab is then started at the same dosing: 140 mg Q2W or 420 mg monthly. Ezetimibe 10 mg daily is often co-prescribed to provide a second non-statin LDL-lowering mechanism 6.

Monitoring timeline. Lipid panels at 4-8 weeks confirm the expected LDL reduction. If the patient achieves a >50% drop from their pre-treatment baseline, the response is typical. Suboptimal responders should be evaluated for adherence (missed injections) or the rare possibility of anti-drug antibody formation, which occurred in <0.5% of patients in clinical trials 9.

Liver function testing is not required for evolocumab, a notable difference from statin initiation protocols.

Side Effect Profiles: What Changes After the Switch

Rosuvastatin's side-effect burden centers on skeletal muscle. Myalgia affects 5-10% of users, with rare cases of rhabdomyolysis (estimated at 1-3 per 100,000 patient-years). New-onset diabetes is a class effect: the JUPITER trial found rosuvastatin increased diabetes incidence by 27% compared to placebo (3.0% vs 2.4%), primarily in patients with pre-existing metabolic risk factors 4. Hepatotoxicity is rare but requires baseline liver enzyme testing per the prescribing information 10.

Evolocumab's profile is different. Injection-site reactions (redness, bruising) are the most common complaint, occurring in approximately 3-5% of patients. Upper respiratory tract infections and influenza-like symptoms appeared at slightly higher rates than placebo in clinical trials. FOURIER found no significant difference in new-onset diabetes, neurocognitive events, or hepatic adverse events between evolocumab and placebo groups over 2.2 years of follow-up 2.

The EBBINGHAUS cognitive substudy of FOURIER specifically assessed neurocognitive function in 1,204 patients achieving very low LDL levels on evolocumab. No difference in cognitive performance was detected between the evolocumab and placebo groups, even among patients whose LDL fell below 25 mg/dL 11.

Patients switching off a statin to evolocumab typically report resolution of myalgia within 2-4 weeks of statin discontinuation. That symptomatic improvement is often the primary motivation for the switch.

Cost, Insurance, and Access Considerations

Generic rosuvastatin costs $10-30 per month at most U.S. pharmacies. This makes it one of the most cost-effective cardiovascular interventions available. Repatha carries a wholesale acquisition cost near $6,000 per year in the United States, though Amgen's list price was reduced from the original $14,000 annual cost following negotiations and competitive pressure from alirocumab (Praluent) 12.

Most commercial insurers and Medicare Part D plans require prior authorization for PCSK9 inhibitors. Typical requirements include documented trial of maximally tolerated statin therapy (usually at least 8-12 weeks), documented statin intolerance or inadequate LDL response, and a diagnosis of ASCVD or heterozygous FH. Step therapy through ezetimibe is usually mandatory before approval.

Amgen's copay assistance program covers up to $150 per month for commercially insured patients, and a patient assistance program exists for uninsured individuals. The practical out-of-pocket cost for most insured patients who obtain prior authorization approval falls between $0 and $150 per month.

The 2022 ACC Expert Consensus Decision Pathway updated its cost-effectiveness threshold, noting that at the reduced pricing, PCSK9 inhibitors approach conventional willingness-to-pay benchmarks for patients with ASCVD and LDL persistently above 70 mg/dL on maximally tolerated statin therapy 12.

Can You Use Both Drugs Together?

Yes. Combination therapy is the standard approach for most patients who need a PCSK9 inhibitor. The FOURIER trial itself was conducted with evolocumab added to background statin therapy: 69.3% of enrolled patients were on high-intensity statin, and 30.4% were on moderate-intensity statin 2.

The pharmacologic rationale is straightforward. Rosuvastatin upregulates hepatic LDL receptor expression. By blocking PCSK9-mediated degradation of those same receptors, evolocumab amplifies the statin's effect. A patient on rosuvastatin 20 mg who achieves 50% LDL reduction (say, from 150 to 75 mg/dL) can expect an additional 50-60% reduction from baseline upon adding evolocumab, potentially reaching an LDL near 30-35 mg/dL.

Triple therapy with rosuvastatin, ezetimibe, and evolocumab produces the greatest LDL reduction. In patients with homozygous FH, this combination has achieved LDL levels below 100 mg/dL in cases where baseline LDL exceeded 400 mg/dL 8.

No dose adjustment of either drug is needed when they are used together. The drugs do not share metabolic pathways; rosuvastatin undergoes minimal CYP450 metabolism, while evolocumab is cleared through receptor-mediated endocytosis and proteolytic degradation 9.

Special Populations: Who Benefits Most From Switching or Adding

Post-ACS patients. The ACC/AHA guidelines recommend initiating high-intensity statin therapy before hospital discharge after an acute coronary syndrome event. If LDL remains at or above 70 mg/dL at the 4-8 week lipid check, adding a PCSK9 inhibitor is a class IIa recommendation. The FOURIER subgroup analysis showed that patients within 2 years of their qualifying MI derived greater absolute benefit from evolocumab than those with more remote events 2.

Patients with peripheral artery disease (PAD). A pre-specified FOURIER subanalysis in 3,642 PAD patients found evolocumab reduced major adverse limb events by 42% (HR 0.58; 95% CI 0.38-0.88) 13. This is a population where aggressive LDL lowering has outsized impact.

Patients with diabetes on statin therapy. Rosuvastatin's diabetogenic effect is modest and generally does not warrant discontinuation. For diabetic patients already on maximum statin and ezetimibe who remain above LDL goal, adding evolocumab is preferred over switching away from the statin. The cardiovascular benefit of the statin persists even in those who develop statin-associated hyperglycemia 10.

Elderly patients (age 75+). The FOURIER subgroup analysis showed consistent LDL reduction across age groups, though the primary endpoint reduction was numerically smaller in patients over 75 (interaction P=0.09). The 2018 AHA/ACC guideline notes that clinical judgment should guide PCSK9 inhibitor use in older adults, factoring in life expectancy, polypharmacy, and functional status 3.

What the Guidelines Say About Sequencing

The 2018 AHA/ACC cholesterol guideline and the 2019 ESC/EAS dyslipidemia guideline both position the treatment sequence as follows: maximize statin dose first, add ezetimibe second, add a PCSK9 inhibitor third. This stepwise approach reflects both the evidence base and cost-effectiveness data 3 7.

The ESC is slightly more aggressive. Their 2019 update recommends an LDL target of <55 mg/dL (compared to the AHA/ACC threshold of <70 mg/dL) for very-high-risk patients, with a further recommendation of <40 mg/dL for patients experiencing a second vascular event within 2 years on maximally tolerated therapy 7.

For statin-intolerant patients, guidelines allow skipping directly to evolocumab plus ezetimibe. The European Atherosclerosis Society (EAS) consensus panel defines statin intolerance as inability to tolerate at least two different statins (one at the lowest approved daily dose) due to symptoms that began or worsened during statin therapy and resolved upon discontinuation 14.

Prescribers considering a switch should document the clinical rationale, the statin trials attempted, and the current LDL gap to target. This documentation is both good clinical practice and a requirement for insurance prior authorization.